Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Eva M. Boorsma, Joost C. Beusekamp, Jozine M. ter Maaten, et al.
European Journal of Heart Failure (2020) Vol. 23, Iss. 1, pp. 68-78
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 256
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 140
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Jan Biegus, Adriaan A. Voors, Sean P. Collins, et al.
European Heart Journal (2022) Vol. 44, Iss. 1, pp. 41-50
Open Access | Times Cited: 140
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 11, pp. 1381-1392
Open Access | Times Cited: 136
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
Faı̈ez Zannad, João Pedro Ferreira, Javed Butler, et al.
European Heart Journal (2022) Vol. 43, Iss. 48, pp. 4991-5002
Open Access | Times Cited: 136
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
Milton Packer, John J.V. McMurray
European Journal of Heart Failure (2021) Vol. 23, Iss. 6, pp. 882-894
Open Access | Times Cited: 130
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 108
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Pieter Martens, Jeffrey M. Testani, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 4, pp. 603-619
Open Access | Times Cited: 93
Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
Zachary L. Cox, Sean P. Collins, Gabriel A. Hernandez, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 14, pp. 1295-1306
Closed Access | Times Cited: 51
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Milton Packer, Christopher S. Wilcox, Jeffrey M. Testani
Circulation (2023) Vol. 148, Iss. 4, pp. 354-372
Open Access | Times Cited: 50
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
Jasper Tromp, Piotr Ponikowski, Afshin Salsali, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 5, pp. 826-834
Open Access | Times Cited: 85
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes
Milton Packer
JACC Heart Failure (2021) Vol. 9, Iss. 8, pp. 535-549
Open Access | Times Cited: 78
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 59
Heart failure: an update from the last years and a look at the near future
Mauro Riccardi, Antonio Maria Sammartino, Massimo Piepoli, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 6, pp. 3667-3693
Open Access | Times Cited: 49
Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
Evelyne Meekers, Jeroen Dauw, Pieter Martens, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3672-3682
Open Access | Times Cited: 35
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
Milton Packer, Javed Butler, Cordula Zeller, et al.
Circulation (2023) Vol. 148, Iss. 13, pp. 1011-1022
Open Access | Times Cited: 33
Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
Pedro E.P. Carvalho, Thiago M. A. Veiga, Ana Cristina Simões e Silva, et al.
Clinical Research in Cardiology (2023) Vol. 112, Iss. 8, pp. 1044-1055
Open Access | Times Cited: 30
Sodium–glucose cotransporter‐2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Jan Biegus, Marat Fudim, Husam M. Salah, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1526-1536
Open Access | Times Cited: 24
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
Panagiotis Stachteas, Athina Nasoufidou, Dimitrios Patoulias, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3122-3122
Open Access | Times Cited: 14
Randomized trial to assess worsening renal function by adding dapagliflozin for acute decompensated heart failure
Shodai Kawanami, Yasuyuki Egami, Masaru Abe, et al.
ESC Heart Failure (2025)
Open Access | Times Cited: 1
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Andrea Natali, Lorenzo Nesti, Domenico Tricò, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 44
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Hui Lin, Frank Geurts, Luise Hassler, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 462-505
Open Access | Times Cited: 37
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use
Christos Siafarikas, Chris J. Kapelios, Μargarita Papatheodoridi, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 884-893
Open Access | Times Cited: 7
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z.I. Cherney, Jacob A. Udell, Daniel J. Drucker
Med (2021) Vol. 2, Iss. 11, pp. 1203-1230
Open Access | Times Cited: 36
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
Riccardo Nevola, Maria Rosaria Alfano, Pia Clara Pafundi, et al.
Reviews in Cardiovascular Medicine (2022) Vol. 23, Iss. 3
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top